Search results

Title: ACCELPharma (semester?), IPRO 353: ACCELPharma IPRO 353 IPRO Day Presentation F06
Creator: Josefsson, Gustaf, Ames, Kerry, Calizo, Milagros, Schiller, Brian, Groth, Kristel, Ervin, Natalia, Holmes, Matt, Lee, Hyun, Lim, Eung, Ravi, Iyengar
Date: 2006-12, 2006-12
Description: AccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development,...
Show moreAccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development, validation, and deployment of personalized medicine models. It differentiates itself by being one of the only companies to correlate side effects of drugs to certain genetic mutations for a broad range of effects. AccelPharma expects to break even and begin to achieve positive revenues after only the second sale.
Deliverables for IPRO 353: ACCELPharma for the Fall 2006 semester.
Show less

Title: ACCELPharma (semester?), IPRO 353: ACCELPharma IPRO 353 Abstract F06
Creator: Josefsson, Gustaf, Ames, Kerry, Calizo, Milagros, Schiller, Brian, Groth, Kristel, Ervin, Natalia, Holmes, Matt, Lee, Hyun, Lim, Eung, Ravi, Iyengar
Date: 2006-12, 2006-12
Description: AccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development,...
Show moreAccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development, validation, and deployment of personalized medicine models. It differentiates itself by being one of the only companies to correlate side effects of drugs to certain genetic mutations for a broad range of effects. AccelPharma expects to break even and begin to achieve positive revenues after only the second sale.
Deliverables for IPRO 353: ACCELPharma for the Fall 2006 semester.
Show less

Title: ACCELPharma (semester?), IPRO 353: ACCELPharma IPRO 353 Poster F06
Creator: Josefsson, Gustaf, Ames, Kerry, Calizo, Milagros, Schiller, Brian, Groth, Kristel, Ervin, Natalia, Holmes, Matt, Lee, Hyun, Lim, Eung, Ravi, Iyengar
Date: 2006-12, 2006-12
Description: AccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development,...
Show moreAccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development, validation, and deployment of personalized medicine models. It differentiates itself by being one of the only companies to correlate side effects of drugs to certain genetic mutations for a broad range of effects. AccelPharma expects to break even and begin to achieve positive revenues after only the second sale.
Deliverables for IPRO 353: ACCELPharma for the Fall 2006 semester.
Show less

Title: ACCELPharma (semester?), IPRO 353: ACCELPharma IPRO 353 Midterm Presentation F06
Creator: Josefsson, Gustaf, Ames, Kerry, Calizo, Milagros, Schiller, Brian, Groth, Kristel, Ervin, Natalia, Holmes, Matt, Lee, Hyun, Lim, Eung, Ravi, Iyengar
Date: 2006-12, 2006-12
Description: AccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development,...
Show moreAccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development, validation, and deployment of personalized medicine models. It differentiates itself by being one of the only companies to correlate side effects of drugs to certain genetic mutations for a broad range of effects. AccelPharma expects to break even and begin to achieve positive revenues after only the second sale.
Deliverables for IPRO 353: ACCELPharma for the Fall 2006 semester.
Show less

Title: ACCELPharma (semester?), IPRO 353
Creator: Josefsson, Gustaf, Ames, Kerry, Calizo, Milagros, Schiller, Brian, Groth, Kristel, Ervin, Natalia, Holmes, Matt, Lee, Hyun, Lim, Eung, Ravi, Iyengar
Date: 2006-12, 2006-12
Description: AccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development,...
Show moreAccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development, validation, and deployment of personalized medicine models. It differentiates itself by being one of the only companies to correlate side effects of drugs to certain genetic mutations for a broad range of effects. AccelPharma expects to break even and begin to achieve positive revenues after only the second sale.
Deliverables for IPRO 353: ACCELPharma for the Fall 2006 semester.
Show less

Title: ACCELPharma (semester?), IPRO 353: ACCELPharma IPRO 353 Final Report F06
Creator: Josefsson, Gustaf, Ames, Kerry, Calizo, Milagros, Schiller, Brian, Groth, Kristel, Ervin, Natalia, Holmes, Matt, Lee, Hyun, Lim, Eung, Ravi, Iyengar
Date: 2006-12, 2006-12
Description: AccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development,...
Show moreAccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development, validation, and deployment of personalized medicine models. It differentiates itself by being one of the only companies to correlate side effects of drugs to certain genetic mutations for a broad range of effects. AccelPharma expects to break even and begin to achieve positive revenues after only the second sale.
Deliverables for IPRO 353: ACCELPharma for the Fall 2006 semester.
Show less

repository.iit